BIIB
BIOGEN INC.NasdaqResearch view
Healthcare · Biological Products, (No Diagnostic Substances) · Large-cap · SEC EDGAR FY 2025-12-31
Price history
Chart: TradingView’s own feed · page prices: 1D EOD🔒 Click to interact · scroll moves the page
Snapshot
SEC EDGAR · FY 2025-12-31SectorHealthcare
Market Cap$31.9B
Enterprise Value$35.2B
Income$1.3B
Sales$9.9B
Book/sh$123.66
Cash/sh$20.38
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio2.03
Current Ratio2.68
Debt/Eq0.34
EPS (ttm)$8.79
EPS this Y-21.4%
EPS past 3/5Y-25.0%
Sales past 3/5Y-0.9%
EPS Y/Y TTM-21.4%
Sales Y/Y TTM2.2%
Shs Outstand147.64M
ROA4.4%
ROE7.1%
ROIC11.0%
Gross Margin—
Oper. Margin28.7%
Profit Margin13.1%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue & Earnings — fiscal year
$11.0B
2021
$10.2B
2022
$9.8B
2023
$9.7B
2024
$9.9B
2025
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $11.0B | $10.2B | $9.8B | $9.7B | $9.9B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $2.8B | — | — | — | — |
| Net Income | $1.6B | $3.0B | $1.2B | $1.6B | $1.3B |
| Diluted EPS | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |
| Operating Cash Flow | $3.6B | $1.4B | $1.5B | $2.9B | $2.2B |
| Free Cash Flow | $3.4B | $1.1B | $1.3B | $2.7B | $2.1B |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
GrossOperatingNet
FY25 cash-flow waterfall
Capital-light: capex is $153.8M against $2.2B operating cash
COMMUNITY · $BIIB0 theses
POST YOUR TAKE →Related Stocks
Click to exploreSame Industry · Biological Products, (No Diagnostic Substances)
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.